Credit Suisse Downgrades Myriad Genetics (MYGN) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
JMP Securities Upgrades Myriad Genetics (MYGN) to Market Outperform
February 4, 2015 7:08 AM ESTJMP Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Market Outperform with a price target of $50.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $38.12 yesterday.
... MoreMizuho Securities Downgrades Myriad Genetics (MYGN) to Neutral
February 4, 2015 7:07 AM ESTMizuho Securities downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Neutral with a price target of $32.00 (from $50.00).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $38.12 yesterday.
... MoreMyriad Genetics (MYGN) CEO to Retire
February 3, 2015 4:11 PM ESTMyriad Genetics, Inc. (Nasdaq: MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously elected Mark C. Capone, currently president of Myriad Genetic Laboratories, Inc., as Mr. Meldrum's successor. Mr. Capone, a 13-year veteran of the company, has worked closely with Mr. Meldrum and the board in charting the strategic direction and managing the overall business of the company, as well as regularly... More
Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
February 3, 2015 4:08 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $184.4 million versus the consensus estimate of $183.41 million.
Myriad Genetics sees FY2015 EPS of $1.50 - $1.55, versus the consensus of $1.85. Myriad Genetics sees FY2015... More
